Canadian Cancer Trials Group Bulletins

Trial Management Group

CO.21 Trial Activation

CO.21 -- The Colon Health and Life-Long Exercise Change (CHALLENGE) trial: A randomized trial of the Canadian Cancer Trials Group -- was centrally activated 3 December 2008.

The purpose of this study is to compare the disease-free survival of patients involved in a physical activity program (designed to increase physical activity participation) who also receive general health education materials (about diet and physical activity) to patients who receive the general health education materials only. This study is being done because, as of yet, there is no conclusive evidence that physical activity will decrease the likelihood of colon cancer recurrence. This study will also obtain important information about the impact of physical activity on patients' physical functioning, body composition, quality of life, fatigue, mood, cytokines and the insulin pathway, and their influence on prognosis, as well as cost-effectiveness.

In order to assess feasibility prior to more widely activating the trial, this study will initially be opened in a select number of preapproved pilot centres. These centres include:
1. Odette Cancer Centre, Toronto, ON
2. Princess Margaret Hospital, Toronto, ON
3. Ottawa Health Research Institute, Ottawa, ON
4. Grand River Regional Cancer Centre, Kitchener / Waterloo, ON
5. BCCA - Vancouver Cancer Centre, Vancouver, BC
6. Cancer Centre of Southeastern Ontario, Kingston, ON
7. Tom Baker Cancer Centre, Calgary, AB
8. Cross Cancer Institute, Edmonton, AB
9. London Regional Cancer Program, London, ON

Broader activation will occur once trial feasibility has been confirmed.

Further trial information, including the trial protocol, is available on the trial website ...

In addition, a publication describing CO.21 is included in the current issue of Current Oncology.
Courneya KS, Booth CM, Gill S, O'Brien P, Vardy J, Friedenreich CM, Au HJ, Brundage MD, Tu D, Dhillon H, Meyer RM. The Colon Health and Life-Long Exercise Change (CHALLENGE) trial (CO.21). Current Oncology 15(6): 8-16, 2008.